Floatz logo

DACTOLISIB

Cowden Syndrome

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Cowden Syndrome cohort.

Asset / SponsorPhaseRating
bgt226
Novartis Pharmaceuticals
Phase 1/2CCC

Same molecule, other indications

DACTOLISIB is also rated in:

breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
pancreatic neuroendocrine tumorDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →